期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Cancer Management and Research LetPub Score 6.3
51 ratings
Rate
Reputation 6.9 Influence 5.0 Speed 9.3 | ||||||||||||||||
期刊簡稱 | CANCER MANAG RES | ||||||||||||||||
ISSN | 1179-1322 | ||||||||||||||||
h-index | 32 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 0.00%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | https://www.dovepress.com/cancer-management-and-research-journal | ||||||||||||||||
在線稿件提交 | https://www.dovepress.com/submit_step_1.php | ||||||||||||||||
開放訪問 | Yes | ||||||||||||||||
出版商 | Dove Medical Press Ltd. | ||||||||||||||||
主題領域 | Medicine | ||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||
發行頻率 | |||||||||||||||||
創刊年 | 0 | ||||||||||||||||
每年文章數 | 111每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 96.28% | ||||||||||||||||
OA Related Info | APC: Yes( USD2990; ) APC waiver:Check Notes Other charges: No Keywords: epidemiology、cancer、anticancer agents、cancer screening、palliative care Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q3
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1179-1322%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 16 Weeks | ||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 | |
[Cancer Management and Research] 的評論 | 撰寫評論 |
作者: 是志丹吖 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-06-21 17:53:45 評論於 Review speed: 6.0 | Submission acceptance rate: 95.0 Emphasized research directions: Oncology; Chronic disease management; Sharing of oncology rehabilitation experiences: Impact factor for 2023 is 2.5 points.(0) 讚! | 是志丹吖 |
作者: 星熊东付 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-29 19:17:24 評論於 It's really slow, keep asking for the raw data(0) 讚! | 星熊东付 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-24 16:35:56 評論於 Received(0) 讚! | 北海雅蓉 |
作者: 一只素芬呀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-09 18:23:06 評論於 It is not convenient to contact co-authors, you often have to send emails to each author and need each author to confirm. Also, it has been 3 weeks since the initial review, finding reviewers is also very slow. When submitting to another journal, ONCOtarget and therapy, after a month and a half, we couldn't find reviewers and had to withdraw the submission(0) 讚! | 一只素芬呀 |
作者: 雾水旭炎 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-03-12 21:54:04 評論於 The period is just two or three months(0) 讚! | 雾水旭炎 |
作者: 不灭幻菱 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-03-11 18:32:12 評論於 So excellent!(0) 讚! | 不灭幻菱 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-02-27 08:47:57 評論於 4A in rework(0) 讚! | 北海雅蓉 |
作者: Rebecca II 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-02-19 14:44:27 評論於 What is your current status now?(0) 讚! | Rebecca II |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-01-22 19:25:52 評論於 1.22 or 2b..., is still only one reviewer, this is too slow, despair(0) 讚! | 北海雅蓉 |
作者: 穿心妙凡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-01-21 23:12:44 評論於 How valuable, currently 1A 3 weeks ?(0) 讚! | 穿心妙凡 |
作者: 凌霄芮波 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-01-05 19:17:53 評論於 Please translate the following paragraph into English and Japanese, and title them as ":" and ":" respectively: 求v(0) 讚! | 凌霄芮波 |
作者: 穿心浩思 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-01-05 11:15:52 評論於 Please translate the following paragraph into English and Japanese and label them as ":" and ":"(0) 讚! | 穿心浩思 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-25 16:30:41 評論於 Please translate the following paragraph into English and Japanese, and title them ": " and ": " respectively: 12.19 2b(0) 讚! | 北海雅蓉 |
作者: 梅花清安 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-25 15:27:45 評論於 Review speed: 3.0 | Submission acceptance rate: 95.0 Emphasis on research direction: Oncology Experience sharing: This journal has a fast acceptance process. Feel free to connect with me if needed(0) 讚! | 梅花清安 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-11 17:47:17 評論於 I think we can send a reminder email once a month(0) 讚! | 北海雅蓉 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-11 15:18:32 評論於 Has it been so long since you invited the reviewers? How long has your 1f been maintained? Mine has just started 1f... I can't wait to graduate(0) 讚! | 北海雅蓉 |
作者: 北海雅蓉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-06 14:01:27 評論於 Recording: Submitted on 23.11.27 1A; 11.30 1ab; 12.02 1e; 12.06 Received email explaining animal ethics issues and uploaded ethics approval; 12.08 1f; 12.11 changed back to 1e, received email requesting original WB image; 12.12 1f; 12.13 2a(0) 讚! | 北海雅蓉 |
作者: 书生小柳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-12-06 09:08:49 評論於 My 2a has been almost a month, and I haven't received any invitations for reviewers yet. Can I ask for a reminder?(0) 讚! | 书生小柳 |
作者: 无冬海雪 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-06 17:10:40 評論於 Have you submitted it for review?(0) 讚! | 无冬海雪 |
作者: 无冬海雪 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-11-05 19:38:17 評論於 How many more days until graduation? I can't wait(0) 讚! | 无冬海雪 |
作者: 千叶超级甜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-27 23:20:23 評論於 It has been 11 days since 1a. How are you now?(0) 讚! | 千叶超级甜 |
作者: 回风嘉蕊 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-10-05 09:31:01 評論於 Still no news after 16 days of the 1A?(0) 讚! | 回风嘉蕊 |
作者: 和风桑 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-23 11:01:02 評論於 Ethical approval is in Chinese in the hospital document, can you upload it?(0) 讚! | 和风桑 |
作者: 深渊绮晴 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-09-14 12:52:51 評論於 We are ready to improve the quality(0) 讚! | 深渊绮晴 |
作者: 经纶小哥哥 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-08 08:23:08 評論於 The official rejection rate in 2022 is 68%(0) 讚! | 经纶小哥哥 |
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 |
Contact us